or Try an Advanced Search...

    Neurological Disorders Stocks List

    Symbol Grade Name % Change
    ENZ F Enzo Biochem, Inc. 2.33
    IONS F Ionis Pharmaceuticals, Inc. -1.50
    RLMD F Relmada Therapeutics, Inc. -1.75
    PRTA F Prothena Corporation plc 0.49
    PMN F ProMIS Neurosciences Inc. -0.73
    ADXN F Addex Therapeutics Ltd 2.98
    AIFF F Firefly Neuroscience, Inc. 0.84
    AEMD F Aethlon Medical, Inc. -1.15
    NLSP F NLS Pharmaceutics Ltd. 0.91
    VAXX F Vaxxinity, Inc. -90.00
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Information Technology Services Medical Devices Scientific & Technical Instruments
    Related Stock Lists: Biopharmaceutical Organ Systems Parkinson's Disease Urological Disorders Alzheimer's Disease Degenerative Disease Amyotrophic Lateral Sclerosis Biology Biotechnology Cancer Dementia Fragile X Syndrome Glaucoma Infectious Diseases Neurodegeneration Neurodegenerative Diseases Neurodegenerative Disorders Psychiatric Diagnosis Rare Neurological Disorders Stage Pharmaceutical

    Related ETFs - A few ETFs which own one or more of the above listed Neurological Disorders stocks.

    Symbol Grade Name Weight
    SBIO C ALPS Medical Breakthroughs ETF 6.49
    MNTL D Tema Neuroscience and Mental Health ETF 5.05
    BBP C BioShares Biotechnology Products Fund 4.94
    IBRN C iShares Neuroscience and Healthcare ETF 4.57
    FBT D First Trust Amex Biotech Index Fund 3.85
    View all Neurological Disorders ETFs...
    Compare ETFs
    Compare MNTL to IBRN Compare SBIO to IBRN Compare SBIO to MNTL

        Neurological Disorders Stocks Recent News

        Date Stock Title
        Nov 20 IONS Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 RLMD Relmada Therapeutics to Present at Jefferies London Healthcare Conference
        Nov 18 IONS Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
        Nov 18 NLSP NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
        Nov 16 AIFF Firefly Neuroscience Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$0.18 loss in 3Q 2023)
        Nov 15 AIFF Firefly Neuroscience reports Q3 results
        Nov 15 PRTA Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
        Nov 14 AIFF Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
        Nov 14 PMN ProMIS Neurosciences GAAP EPS of $0.31 beats by $0.38
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Information Technology Services Medical Devices Scientific & Technical Instruments
        Related Stock Lists: Biopharmaceutical Organ Systems Parkinson's Disease Urological Disorders Alzheimer's Disease Degenerative Disease Amyotrophic Lateral Sclerosis Biology Biotechnology Cancer Dementia Fragile X Syndrome Glaucoma Infectious Diseases Neurodegeneration Neurodegenerative Diseases Neurodegenerative Disorders Psychiatric Diagnosis Rare Neurological Disorders Stage Pharmaceutical
        Neurological Disorders

        Neurological disorders are conditions that affect the nervous system, which includes the brain, spinal cord, and nerves. These disorders can affect how the body functions, including movement, speech, and memory. Examples of neurological disorders include Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, epilepsy, and migraine.

        Browse All Tags